Compare Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
High Debt company with Weak Long Term Fundamental Strength
- The company is Net-Debt Free
2
Risky -
3
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
HKD 864 Million ()
NA (Loss Making)
NA
0.00%
-0.49
-5.50%
0.35
Revenue and Profits:
Net Sales:
257 Million
(Quarterly Results - Jun 2026)
Net Profit:
34 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.14%
0%
1.14%
6 Months
0%
0%
0.0%
1 Year
42.02%
0%
42.02%
2 Years
0.38%
0%
0.38%
3 Years
-21.47%
0%
-21.47%
4 Years
-47.23%
0%
-47.23%
5 Years
-55.35%
0%
-55.35%
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-7.43%
EBIT Growth (5y)
-198.02%
EBIT to Interest (avg)
-9.55
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.49
Tax Ratio
1.96%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.69%
ROE (avg)
5.95%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.32
EV to EBIT
2.87
EV to EBITDA
4.45
EV to Capital Employed
-0.45
EV to Sales
-0.71
PEG Ratio
NA
Dividend Yield
1.35%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-6.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bearish
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
256.90
168.20
52.73%
Operating Profit (PBDIT) excl Other Income
52.60
18.60
182.80%
Interest
0.10
0.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
33.50
8.60
289.53%
Operating Profit Margin (Excl OI)
120.80%
-15.00%
13.58%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 52.73% vs 13.80% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 289.53% vs 105.54% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
739.10
765.50
-3.45%
Operating Profit (PBDIT) excl Other Income
-90.80
80.80
-212.38%
Interest
0.80
0.70
14.29%
Exceptional Items
0.00
-4.30
100.00%
Consolidate Net Profit
-171.10
42.80
-499.77%
Operating Profit Margin (Excl OI)
-238.20%
-10.90%
-22.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -3.45% vs -18.32% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -499.77% vs -64.27% in Dec 2024
About Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd. 
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






